RÉSUMÉ
Background@#The correlation between hepatitis B, C viruses (HBV, HCV) and B cell non-Hodgkin’s Lymphoma (B-NHL) and reducing mortality have been studied extensively worldwide@*Objective@#In this study, we aimed to determine the prevalence of HBsAg and anti-HCV positive cases among B-NHL patients and its influence on the survival rate of these patients (on ≤12 months).@*Materials and Methods@#We have done a retrospective analysis on patients who aged over 20 years and newly diagnosed at the Hematology Center of the First State Hospital between 2015-2018. The patients’ information was collected according the study ethics. We divided the patients into 2 groups, survival rate less than 12 months (≤12 months) and survival rate more than 13 months (≥13 months), and compared them regarding age, gender, seroprevalence, and Ann-Arbor stage. @*Results@#Overall, 226 patients (107 males and 119 females with average 54.4) were enrolled in the study. There were 15% HBsAg positive and 41,6% anti-HCV positive cases, while Baatarkhuu et al. (2005) reported (11.8%, 15.6%; p=0.160, p<0.00001) and Bekhbold et al. (2013) reported (11.1%, 10.6%; p=0.055, p<0.00001) in apparently healthy population. Moreover, anti-HCV positive cases among B-NHL patients were higher (p<0.00001) than those (27%) among hepatocellular carcinoma (HCC) patients and same (p=0.404) with those (39%) among liver cirrhosis patients in Mongolia (Bolormaa et al., 2009). Furthermore, 72.0% of all subjects in III-IV stages was accounted for HBsAg, anti-HCV positive group which had ≤12 months, while 52.1% of them was accounted for HBsAg, anti-HCV positive group which had ≥13 months and was statistical significantly lower (p=0.02).@*Conclusion@#Anti-HCV and HBsAg positive cases might contribute to survival rate with the B-NHL patients diagnosed at the III-IV stages. HCV prevalence among B-NHL subjects was significantly higher than that among the general population prevalence and was same with anti-HCV positive prevalence among the HCC.
RÉSUMÉ
BACKGROUND: Primary cutaneous lymphomas are very rare type of malignant lymphomas. They represent a heterogeneous group of T-cell and B-cell lymphomas with considerable variations in clinical presentation, histopathology, immunophenotype, and prognosis. In this report, we evaluated the clinical characteristics of primary cutaneous lymphoma according to their clinical stages and histopathologic types. METHODS: From January, 1985 to Jun, 1999, 23 patients with histopathologic diagnosis of primary cutaneous lymphoma were evaluated retrospectively. RESULTS: The mean age was 48.5 years at the time of diagnosis of primary cutaneous lymphomas, and the most frequent form of cutaneous involvement was nodule(35%). The average duration from the occurrence of cutaneous lesion to the diagnosis of primary cutaneous lymphoma was 29.8 months. There were 20 cases(87%) of primary cutaneous T cell lymphomas, whereas primary cutaneous B cell lymphomas were seen in 3 cases(13%). The patients with stage I were 9 cases(39%), whereas the patients with stage IV were 10 cases(43%). Complete remission rate was 29% and partial remission rate was 57%. Median disease-free survival duration was 7 months and median overall survival duration was 33 months. One-year overall survival rate was 63.3% and 3-year overall survival rate was 56.3%. CONCLUSION: Primary cutaneous lymphomas were usually diagnosed at a far-advanced stage, and showed poor treatment results. Therefore early diagnosis is important to improve the survival rate. There should be carefully follow-up and repeated tissue diagnosis of the skin lesions which had a suspicion of primary cutaneous lymphoma and had not responded to conservative treatment.